FMMC REPORT
September 2023
| |
Excite Medical Honored among University of South Florida's Fast 56 |
The University of South Florida (USF) recently recognized Tampa-based Excite Medical as one of the fastest growing USF alumni-lead companies for the 2nd year in a row. The USF Fast 56 identifies, recognizes, and celebrates the 56 fastest-growing USF Bull-owned or Bull-led businesses in the world. The USF Fast 56 not only celebrates their success, but also provides a forum to pass lessons to the next generation of USF entrepreneurs. Accepting the award at the recent USF Fast 56 ceremony was Saleem Musallam, Excite Medical’s Founder and CEO. Excite Medical is an innovative manufacturer, supplier, and distributor of advanced medical devices in the field of back and neck pain management.
| | |
TouchPoint Medical Networking Event & Plant Tour This Week |
The FMMC will be Pasco County on Thursday (9/21) for some industry networking, a light breakfast, important legislative updates, and a special tour of TouchPoint Medical's state-of-the-art 142,000sf manufacturing facility and global headquarters. TouchPoint Medical focuses on developing customer-driven solutions that advance healthcare professionals’ delivery of care. TouchPoint Medical is a global provider of innovative and intelligent solutions spanning both Point-of-Care Mobile and Stationary Workstations and Medication Delivery and Management to thousands of hospitals and health care facilities around the world. Come jin us for this special FMMC event. For more information and to register for the event, click HERE.
| |
Emergency Bridge Loan Program Activated |
For member companies impacted by Hurricane Idalia, Governor DeSantis recently activated the Florida Small Business Emergency Bridge Loan Program, making $20 million available for short-term, zero-interest loans to small businesses. Interested applicants can apply now through October 25, 2023. Businesses in the following counties, including sole proprietors, are eligible to apply: Alachua, Baker, Bradford, Citrus, Columbia, Dixie, Franklin, Gilchrist, Hamilton, Hernando, Hillsborough, Jefferson, Lafayette, Leon, Levy, Madison, Manatee, Marion, Pasco, Pinellas, Sumter, Suwannee, Taylor, Union and Wakulla counties.
| |
Medical Device User Fees for Fiscal Year 2024
The FDA recently issued a Federal Register notice announcing medical device user fees and annual establishment registration fees for Fiscal Year 2024 (FY 2024), effective October 1, 2023. The establishment registration user fee for FY 2024 is $7,653, and there are no waivers or reductions for small establishments or businesses. Other fees for Fiscal Year 2023 are as follows:
| |
The FDA is accepting Small Businesses Fee Reduction and Fee Waiver requests for FY 2024. Before submitting a request, you must be certified as a “small business.” Learn more at Reduced Medical Device User Fees: Small Business Determination (SBD) Program.
Voluntary Improvement Program
The U.S. Food and Drug Administration (FDA) recently issued the final guidance: Fostering Medical Device Innovation: FDA Activities and Engagement with the Voluntary Improvement Program. The Voluntary Improvement Program is facilitated through the Medical Device Innovation Consortium and uses third-party appraisals to evaluate a medical device manufacturer’s practice, and their capability and performance in producing high quality devices. The guidance outlines the program’s features, benefits, operations, and eligibility considerations.
Reminder: eSTAR and CDRH Portal are Required for 510(k) Submissions
The FDA is reminding all medical device submitters that starting October 1, 2023, all 510(k) submissions, unless exempted, must be submitted as electronic submissions using eSTAR through the CDRH Portal as noted in the Electronic Submission Template for Medical Device 510(k) Submissions final guidance. eSTAR is the only available electronic submission template to facilitate the preparation of 510(k) electronic submissions.
Use of International Standard ISO 10993-1 (Biocompatibility) / Webinar
The FDA recently issued the final guidance: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process.” The final guidance reflects the FDA's current thinking about the type of biocompatibility information that should be provided in a medical device premarket submission for certain devices in contact with intact skin (see Attachment G of the guidance). On October 12, 2023, the FDA will host a webinar for industry and others interested in learning more about the guidance.
Modernizing the Premarket Notification 510(k) Program
The FDA recently issued the following three draft guidances intended to support efforts to continue to strengthen and modernize the 510(k) Program and advance the safety and effectiveness of medical devices as they become more complex and innovative:
Breakthrough Devices Program & Health Equity
The FDA recently issued an update to the final guidance: Breakthrough Devices Program. The updates align with the actions outlined in the FDA’s Center for Devices and Radiological Health (CDRH) Strategic Priorities to Advance Health Equity by supporting innovation of new and existing technologies that address health inequities.
Medical Device Development Tools
The FDA recently announced the qualification of a new tool through the voluntary Medical Device Development Tools (MDDT) program: Accelerated Testing to Prove Long-Term Material Biostability. The new MDDT is a non-clinical assessment model intended to assess long-term hydrolytic biostability of thermoplastic polyurethane materials being considered for cardiac or neuromodulation lead insulation.
Off-The-Shelf (OTS) Software
The FDA recently issued the final guidance Off-The-Shelf Software Use in Medical Devices - Guidance for Industry and Food and Drug Administration Staff. This guidance document provides information regarding the recommended documentation sponsors should include in a premarket submission for FDA’s evaluation of off-the-shelf (OTS) software used in a medical device.
| |
Public Meeting: Modernizing Recalls of FDA-Regulated Commodities
The FDA is announcing a public meeting titled Modernizing Food and Drug Administration Recalls Listening Session, to be held Friday, September 29, 2023 (9:00 a.m. to 5:00 p.m. ET/Virtual & In-Person). The purpose of this public meeting is to provide an opportunity for stakeholders to share information and feedback about topics related to recall modernization for FDA-regulated products.
Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot
The FDA recently announced that beginning October 1, 2023, the TAP Pilot will expand to include devices in the Office of Neurological and Physical Medicine (OHT5). TAP is intended to help ensure that U.S. patients have access to high-quality, safe, effective, and innovative medical devices first in the world for years to come by promoting early, frequent, and strategic communications between the FDA and medical device sponsors.
Hydrogen Peroxide-Based Contact Lens Care Products
The FDA recently issued the final guidance: Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions. This final guidance provides labeling recommendations for manufacturers of hydrogen peroxide-based contact lens care products for inclusion in premarket notification (510(k)) submissions.
Medical Device Shortages List
The FDA recently updated the Medical Device Shortages List web page to remove the following product codes:
- Specimen Collection – Testing Supplies and Equipment (codes: JKA, GIM, and KXG)
- Laboratory Reagents and Testing Supplies – Testing Supplies & Equipment (product codes: QOF, JRC, LXG, PPM, NSU, OOI, and JJH)
- Transport Media Device – Testing Supplies & Equipment (codes: LIO, QBD, and JSM)
- Saline, Vascular Access Flush – General ICU/ Hospital Products (product code: NGT)
- Certain Ventilation-Related Products – (product codes: BZD, MNS, and MNT)
- Oxygenators intended for extracorporeal circulation (product codes: DTZ and BYS)
Electronic Medical Device Export Documents
The FDA recently announced that, in December 2023, it will begin transitioning from paper export documents for medical devices to electronic export documents. Starting January 2, 2024, requestors and foreign governments will be able to verify the authenticity of an export certificate through the FURLS Export Certificate Validator (FECV) database. The FDA will include a link to the FECV database at the bottom of each certificate.
| |
Florida Workers’ Compensation Rates Continue Decline
For the 7th straight year, the National Council on Compensation Insurance (NCCI) has proposed an average 15.1% Workers’ Compensation (WC) premium decrease in Florida for 2024. The filing must be reviewed and approved by the Florida Office of Insurance Regulation to go into effect. This NCCI filing was based on experience data from policy years 2020 and 2021 and comes despite upward pressure on medical costs noted in the analysis.
State Budget Surpluses Strong but Trending Downward
The Joint Legislative Budget Commission met recently to review Florida’s long-range financial outlook. The conclusion was Florida’s budget picture remains healthy with a forecasted general-fund surplus of $7 billion projected for fiscal year 2024-2025. However, it was noted that these budget surpluses are trending downward to $2.72 billion forecasted by fiscal year 2026-2027.
Apprentice Florida & Workforce Development Month
September is Workforce Development Month and it’s a time to recognize the contributions of workforce professionals and the importance of equipping Floridians with the education, training and skills needed to advance their careers and bolster our economy. Registered apprenticeship programs are a proven solution for businesses to recruit, train and retain highly skilled workers. One innovative effort is Apprentice Florida, a partnership between the Florida Department of Education, CareerSource Florida and FloridaCommerce. Apprentice Florida provides businesses with information and resources to establish or expand registered apprenticeship programs, which are a proven solution for businesses to recruit, train and retain highly skilled workers. Learn more HERE.
| |
510(k) Modernization 2023
By Lisa M. Baumhardt, Senior Medical Device Regulation Expert & Adrienne R. Lenz, Principal Medical Device Regulation Expert
On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents. This announcement addresses one of the commitments in FDA’s Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health.
In the announcement, FDA highlights the Safety and Performance Based Pathway launched in 2019, which we blogged about here, noting that there are now ten device-specific final guidances allowing use of this pathway for clearance of the following device types: Spinal Plating Systems, Orthopedic Non-Spinal Metallic Bone Screws and Washers, Magnetic Resonance Receive-Only Coils, Cutaneous Electrodes for Recording Purposes, Conventional Foley Catheters, Fracture Fixation Plates, Surgical Sutures, Denture Base Resin, Facet Screw Systems, and Soft (Hydrophilic) Daily Wear Contact Lenses.
The electronic Submission Template and Resource (eSTAR) program, which we blogged about here and here, also makes the highlight reel given its aim to improve consistency and efficiency in how 510(k)s are prepared. Use of the eSTAR template for 510(k)s becomes mandatory on October 1, 2023 (unless exempt as described in the final guidance).
The biggest news in the announcement is the release of three draft guidance documents, which will be the subjects of future blog posts:
Finally, the announcement notes that FDA will be engaging with manufacturers that are marketing pre-amendment status devices to ensure that the preamendment status for these devices is still applicable. As a reminder, devices with preamendment status are those that were legally marketed in the US before May 28, 1976, have not been significantly changed since May 28, 1976, and for which a regulation requiring a premarket approval application has not been published.
[CONTINUE]
Reprinted with permission of Hyman, Phelps & McNamara, P.C.
| |
European Association of Notified Bodies Releases Report on MDR Transition
By Oliver Eikenberg and Evangeline Loh
|
The European Association of Medical Devices Notified Bodies, Team-NB, released a white paper on August 10, 2023, called “New MDR Transition Timelines and Notified Body Capacity” (TEAM-NB Position Paper). The white paper presents the developments since 2021 and describes the current regulatory situation for manufacturers and Notified Bodies of from the latest amendments through the transitional provisions of Regulation (EU) 2023/607 to the Medical Devices Regulation (MDR, 2017/745).
Team-NB outlines the recent challenges and changes in the current state of Notified Body capacity, such as the greater flexibility when reviewing MDR applications in time through the use of items addressed in MDCG 2022-14. But Team-NB also requests that manufacturers should file timely MDR applications and should submit complete technical documentation files compliant with the MDR to secure a successful transition and timely review.
Introduction to the Notified Body capacity position paper
The position paper presents reasons (risk of medical device shortages as well as delayed and incomplete applications) why it was necessary to amend the MDR transition timelines again in order to give manufacturers more time to bring existing products into compliance with the MDR.
Team NB summarizes the results from their surveys conducted between 2021 and 2023 to identify the number of applications (and Certificates) from manufacturers and the respective capacity of the Notified Body. It is worth reviewing these survey results, as they provide a detailed picture of the real number of MDR applications. For example, the information that many of these applications include a smaller scope than the one covered by the directive certificates (which can be due to a lack of readiness of MDR Technical Documentation Files for numerous devices, as well as a staggered approach taken by manufacturers to certify their product portfolio gradually).
Further, Team-NB shares an overview of the volume of Medical Device Coordinating Group (MDCG) documents and unharmonized national procedures. It calculates that the MDCG has produced more than 80 documents amounting to 1,500 pages of guidance. And Team-NB opines that the “sheer volume” “necessitates an extensive allocation of resources.”
Measures to guarantee sufficient Notified Body capacity
Team-NB posits seven factors that would be critical to facilitate sufficient Notified Body capacity. Team-NB explains the background (implemented solutions and activities) and discusses the current remaining limitations.
[CONTINUE]
Reprinted with permission of Emergo Group, a UL company
| |
Florida Medical Manufacturers Consortium
(850) 270-3158
| |
| | | |